Bill Text

Bill Information


PDF |Add To My Favorites |Track Bill | print page

ACR-101 Pediatric cancer. (2019-2020)

SHARE THIS:share this bill in Facebookshare this bill in Twitter
ACR101:v97#DOCUMENT

Assembly Concurrent Resolution No. 101
CHAPTER 2

Relative to pediatric cancer research.

[ Filed with Secretary of State  January 31, 2020. ]

LEGISLATIVE COUNSEL'S DIGEST


ACR 101, Lackey. Pediatric cancer.
This measure would call for increased research on the causes, cures, and early detection of pediatric cancer.
Fiscal Committee: NO  

WHEREAS, Pediatric cancer is the leading cause of death by disease past infancy among children in the United States; and
WHEREAS, In 2018, it was estimated that nearly 1,800 children died from cancer in the United States; and
WHEREAS, In California, the rate of new cancer diagnoses now stands at 17.4 per 100,000 children, which equals about 15,000 new diagnoses yearly in children from birth to 19 years of age in the United States; and
WHEREAS, Twelve percent of children diagnosed with cancer do not survive; and
WHEREAS, Neuroblastoma is by far the most common cancer in infants and young children and in two out of three cases, by the time the cancer is found, it has metastasized to other parts of the body; and
WHEREAS, Most cancers found in children are treated with chemotherapy because of the ability of pediatric cancers to move quickly through the body of a child, and these treatments are known to create significant health consequences; and
WHEREAS, The average age of children when they are diagnosed is about one to two years of age and nearly 90 percent of cases are diagnosed by five years of age; now, therefore, be it
Resolved by the Assembly of the State of California, the Senate thereof concurring, That more research needs to be conducted on the causes and cures for pediatric cancer and ways in which to detect the cancer early on; and be it further
Resolved, That the Chief Clerk of the Assembly transmit copies of this resolution to the author for appropriate distribution.